tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

VOR Stock Latest News

Vor Biopharma’s Chief Medical Officer Resigns
Company AnnouncementsVor Biopharma’s Chief Medical Officer Resigns
1M ago
8K
VOR
Vor Bio Advances in Clinical Trials and Secures Funding
PremiumCompany Announcements
Vor Bio Advances in Clinical Trials and Secures Funding
1M ago
VOR
Optimistic Buy Rating for Vor Biopharma Amidst Economic Challenges and Promising Clinical Potential
PremiumRatings
Optimistic Buy Rating for Vor Biopharma Amidst Economic Challenges and Promising Clinical Potential
1M ago
VOR
Optimistic Buy Rating for Vor Biopharma Amid Promising Clinical Developments and Stable Financial Position
PremiumRatings
Optimistic Buy Rating for Vor Biopharma Amid Promising Clinical Developments and Stable Financial Position
1M ago
VOR
Vor Bio price target lowered to $5 from $12 at Stifel
PremiumThe Fly
Vor Bio price target lowered to $5 from $12 at Stifel
1M ago
VOR
Vor Bio price target lowered to $13 from $17.50 at H.C. Wainwright
PremiumThe FlyVor Bio price target lowered to $13 from $17.50 at H.C. Wainwright
1M ago
VOR
Vor Bio files $350M mixed securities shelf
Premium
The Fly
Vor Bio files $350M mixed securities shelf
1M ago
VOR
VOR Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
VOR Upcoming Earnings Report: What to Expect?
2M ago
VOR
Vor Bio presents research on patients participating in CGT trials
PremiumThe Fly
Vor Bio presents research on patients participating in CGT trials
3M ago
VOR
Vor Biopharma Approves Stock Option Repricing Strategy
PremiumCompany Announcements
Vor Biopharma Approves Stock Option Repricing Strategy
3M ago
8K
VOR
Vor Bio files to sell 125.71M shares of common stock for holders
PremiumThe Fly
Vor Bio files to sell 125.71M shares of common stock for holders
3M ago
VOR
Vor Biopharma Strengthens Board with New Appointment
PremiumCompany Announcements
Vor Biopharma Strengthens Board with New Appointment
4M ago
8K
VOR
Vor Bio appoints Kalir to board of directors
PremiumThe FlyVor Bio appoints Kalir to board of directors
4M ago
VOR
Vor Bio price target lowered to $6 from $12 at JMP Securities
Premium
The Fly
Vor Bio price target lowered to $6 from $12 at JMP Securities
4M ago
VOR
Vor Biopharma Secures $55.6M for Cancer Therapy Trials
Premium
Company Announcements
Vor Biopharma Secures $55.6M for Cancer Therapy Trials
4M ago
8K
VOR
Vor Bio prices 55.87M shares at 99.425c in private placement
PremiumThe Fly
Vor Bio prices 55.87M shares at 99.425c in private placement
4M ago
VOR
Vor Bio trem-cel relapse-rate remains low, says Oppenheimer
PremiumThe Fly
Vor Bio trem-cel relapse-rate remains low, says Oppenheimer
5M ago
VOR
Vor Bio announces updated data from Phase 1/2 VBP1-1 study
PremiumThe Fly
Vor Bio announces updated data from Phase 1/2 VBP1-1 study
5M ago
VOR
Vor Biopharma Reports Promising Phase 1/2 Study Results
PremiumCompany Announcements
Vor Biopharma Reports Promising Phase 1/2 Study Results
5M ago
8K
VOR
Vor Bio price target lowered to $8 from $10 at Oppenheimer
PremiumThe FlyVor Bio price target lowered to $8 from $10 at Oppenheimer
6M ago
VOR
Vor Bio price target lowered to $14 from $22 at Baird
Premium
The Fly
Vor Bio price target lowered to $14 from $22 at Baird
6M ago
VOR
Vor Biopharma Reports Q3 2024 Financial Results
Premium
Company Announcements
Vor Biopharma Reports Q3 2024 Financial Results
6M ago
VOR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >